Status:
COMPLETED
Seven Year Update of Macular Degeneration Patients
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Age-related Macular Degeneration
Eligibility:
All Genders
55+ years
Brief Summary
The purpose is to assess long term vision outcomes and disease status in patients with age-related macular degeneration previously treated with ranibizumab as participants in the Phase 3 ANCHOR and MA...
Detailed Description
This is a cross-sectional cohort study of exudative age-related macular degeneration (AMD) patients seven or more years after initiation of the intravitreal ranibizumab regimen in the treatment arms o...
Eligibility Criteria
Inclusion
- previous participants in the ANCHOR or MARINA studies, and...
- who were assigned to one of the ranibizumab treatment arms, and...
- who were enrolled in the HORIZON extension study with a current SEVEN UP investigator
- ability to provide written informed consent and comply with study assessments
Exclusion
- any separate ophthalmologic condition that the investigator believes would interfere with anatomic assessments in the trial
Key Trial Info
Start Date :
December 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT01256827
Start Date
December 1 2010
End Date
April 1 2013
Last Update
November 14 2013
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina-Vitreous Associates
Beverly Hills, California, United States, 90211
2
USC Keck School of Medicine, Doheny Eye Institute
Los Angeles, California, United States, 90033
3
Northern California Retina Vitreous Associates
Mountain View, California, United States, 94040
4
University of California San Francisco
San Francisco, California, United States, 94143